The global antiviral immunoglobulin market was valued at USD 4.6 billion in 2022 and is projected to grow significantly, reaching USD 10.9 billion by 2033. According to recent research, the market is expected to expand at a robust CAGR of 7.4% during the forecast period from 2023 to 2033. This growth is primarily driven by the increasing prevalence of viral infections, advancements in healthcare infrastructure, and improvements in intravenous (IV) administration techniques.
Key Growth Drivers
Several factors are contributing to the anticipated expansion of the antiviral immunoglobulin market:
- Rising Incidence of Viral Infections: The global rise in viral infections, including influenza and hepatitis, is driving the demand for effective antiviral treatments, including immunoglobulin therapies.
- Enhancements in Healthcare Infrastructure: As healthcare systems continue to evolve, the availability and accessibility of antiviral treatments are improving, supporting market growth.
- Advancements in IV Administration Techniques: Innovations in IV administration are making treatment more efficient and effective, encouraging healthcare providers to utilize immunoglobulin therapies more widely.
Immunoglobulins have traditionally assisted in opsonization, bacteriolysis stimulation, and toxin neutralization in bacterial infections. In viral infections, immunoglobulins prevent the infection of uninfected cells, support antibody-directed cell-mediated cytotoxicity by natural killer cells, and neutralize viruses either alone or in conjunction with complement. They offer a rapid, safe, and cost-effective approach to obtaining valuable information about an individual’s health status.
Due to the global increase in immunosuppression caused by conditions such as AIDS, organ transplantation, tumors, autoimmune diseases, and the emergence of multidrug-resistant organisms, there is a renewed interest in the use of antibody preparations for preventing infections in high-risk populations. Substantial research has demonstrated that therapies aiming to promote or enhance the immune response may be feasible and beneficial for immunocompromised individuals.
Overall, immunoglobulins play a crucial role in various aspects of immune defense, providing targeted protection against pathogens and contributing to the well-being of individuals, particularly those with compromised immune systems.
Key Market Players
Biotest AG, Baxter International Inc., Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc., Kedrion Biopharma, BDI Pharma Inc., Bayers, Baxalta Incorporated, Kedrion SPA, AstraZeneca PLC., Omrix Biopharma, Sanofi, Cangene corporation.
Competitive Landscape
The population may become less in need of antiviral treatments due to population immunity brought on by high vaccination rates and prior diseases.
- In February 2022, the FDA approved Bebtelovimab, a novel antibody medication developed by AbCellera and Eli Lilly, for the treatment of the Omicron variant of COVID-19. The FDA’s approval signifies the recognition of Bebtelovimab’s efficacy and safety profile, offering healthcare professionals a valuable tool in managing and treating COVID-19 cases, particularly those at higher risk of severe illness.
- In April 2023, SAB Biotherapeutics’ SAB-176 received fast-track designation from the FDA. This designation was granted to expedite the development and review process of SAB-176, a potential treatment for Type A and Type B influenza.
- By 2022, it is anticipated that Western pharmaceutical companies including AstraZeneca Plc. (AZN.L), BioNTech SE (22UAy.DE), Gilead Sciences Inc. (GILD.O), Merck & Co. (MRK.N), Moderna Inc. (MRNA.O), and Pfizer Inc. (PFE.N) will have earned nearly $100 billion from COVID vaccines and therapies.
- By 2022, Western pharmaceutical companies, including AstraZeneca Plc., BioNTech SE, Gilead Sciences Inc., Merck & Co., Moderna Inc., and Pfizer Inc. have generated revenue of nearly $100 billion from COVID vaccines and therapies. The substantial earnings generated reflect the high demand for COVID vaccines and therapies, highlighting the global scale of the market and the financial success of these pharmaceutical companies in addressing the ongoing public health crisis.
With technological advances in the pharmaceutical sector, Antiviral Immunoglobulin will be useful in countering viral infections.
Key Market Segments Covered in the Antiviral Immunoglobulin Industry Research
By Route of Administration:
- Intravenous
- Subcutaneous
- Intramuscular Injections
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Store
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- MEA
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
